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Supplementary Figure 1. Specific MAIT cell activation in response to 
viruses.  
(a, b, c) PBMC’s from healthy individuals were co-cultured with autologous 
monocyte derived dendritic cells (DC’s) exposed to Dengue Virus (DENV). 
Proportion of indicated cell population (n=4-8) expressing IFN-γ (a) or TNF-α 
(b) or CD38 (c) in response to DENV or 100 ng/ml PMA and 500 ng/ml 
Ionomycin. (d) MOI-dependent activation of MAIT cells in an influenza virus-
exposed PBMC culture (n=5-8). (e) Percentage of MAIT cells expressing IFN-
γ in response to influenza virus in the following culture conditions: CD8+ T-
cells only (n=20), PBMC only (n=20), or CD8+ T cells co-cultured with 
macrophages either cultured in the presence of GM-CSF (MΦ or GM-MΦ 
(n=15)) or M-CSF (M-MΦ (n=15)), mature Dendritic Cells (mDC (n=15)), 
monocytes (MC (n=15)), THP-1 cells (n=13), immature DC’s (imDC (n=15)) or 
B-cells (n=10). (f) CD8+ T cells isolated from PBMC’s from healthy individuals 
were co-cultured with exposed to HCV in the presence (n=11) in the absence 
of macrophages. IFN-γ expression by indicated cell population. Data are 
representative from at least two independent experiments. Bars represent 
means ± s.e.m.   (g-i) CD8+ T cells isolated from PBMC’s from healthy 
controls co-cultured with macrophages exposed to HCV as described in 
“methods”, unless indicated otherwise. (h, i) Increasing HCV MOI. (h) 
Representative flow cytometry plot. Percentage of CD69 (f, n=4-12) and IFN-γ 
(i, n=4-12) expression by MAIT cells. All data are representative from at least 
two independent experiments. Symbols and bars represent means ± s.e.m. 
Statistical significance Kruskal-Wallis test followed by Dunns’ test (g, j). ns > 
0.05, P  0.05, ****P ≤  0.0001.   
Supplementary Figure 2 
 
Supplementary Figure 2. Triggering of MAIT cells by cytokines.  
(a-c) PBMC’s (n=8) were stimulated for 24 h with the indicated cytokines, or 
combinations thereof. IFN-γ expression in CD161++CD8+ T cells (b) and 
CD161-CD8+ T cells (c) analysed by flow cytometry. (a) Representative plots. 
(d-f) PBMC’s (n=5) were stimulated for 6 days with the indicated cytokine and 
Granzyme B was analysed in MAIT cells (e), CD161-CD8+ T cells and MAIT 
cells (f). Representative dot plots (d). Bars represent means ± s.e.m. 
Statistical significance was determined with Kruskal-Wallis test followed by 
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Supplementary Figure 3 
 
Supplementary Figure 3. Differences in MAIT cell responses in response to 
different cytokines. PBMC’s from healthy individuals (n=3) were stimulated 
with the indicated concentration of a single cytokine (clear symbols) or 
combination of cytokines (black symbols – the concentration of one cytokine 
being fixed as indicated). Symbols represent mean ± s.e.m. (a) TNF-α, (b) 
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Supplementary Figure 4 
 
Supplementary Figure 4. Triggering of MAIT cells via toll-like receptors. 
PBMC’s were cultured in the presence of TLR ligands for 24 h in the presence 
or absence of blocking antibodies again IL-12 and IL-18 or MR1. IFN-γ 
expression (top chart) and IL-18Rα (bottom chart) expression by MAIT cells 
were analysed by flow cytometry (gated on live CD3+CD8+CD161++Vα7.2+ 
cells). Representative dot plots of IFN-γ expression are shown in the top 




Supplementary Figure 5 
 
Supplementary Figure 5. UV-inactivation of viruses and MAIT cell activation.  
UV inactivation of viruses was achieved using a UV lamp (Fisher Scientific 
UVS-18 EL hand held 220V 50Hz 8W 254 nm white light). Cells were 
exposed to (MOI=1): (a) DENV or UV-inactivated DENV (DENV UV) (n=5), (b) 
HCV or UV-inactivated HCV (HCV UV) (n=7), (c) Influenza A virus or UV-
inactivated influenza A virus (n=10). (d) Infection rates of DENV infected 
APC’s (n=9, MOI=1) were confirmed by intracellular staining of the non-
structural DENV protein NS3 by flow cytometry. (e) APC’s (n=4) and Huh7.5 
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luciferase expression was measured 4 days post infection (f). blood-derived 
APC’s (n=3) or embryonic stem cell derived (es) APC’s  (n=3) or MDBK cells 
(n=1) were treated with Influenza A virus (MOI=2). Replication was 
determined using a plaque assay. (g) Correlation of infection rates of DENV 
infected APC’s against MAIT cell IFN-γ expression by Spearman rank 
correlation test. Bars represent means ± s.e.m. Statistical significance was 
determined with Mann-Whitney test. ns > 0.05,  *P  0.05, **P ≤  0.01 
Supplementary Figure 6 
 
Supplementary Figure 6. Viral MAIT cells triggering is mediated by 
cytokines. (a) Influenza Virus-exposed PBMC culture as described in 
“methods”. Isotype control, anti-MR1, anti-IL-12, anti-IL-15 and/or anti-IL-18 
antibodies were added to the co-culture (n=5-29). IFN-γ expression is shown 
relative to the isotype control. Bars represent means ± s.e.m. Statistical 
significance was determined with Kruskal-Wallis test followed by Dunns’ test. 
ns > 0.05, * P  0.05.  (b) IL-15R mRNA expression in HCV-exposed 




































































Supplementary Figure 7 
 
Supplementary Figure 7. Dose-dependent activation of MAIT cells by IFN-α. 
PBMC’s from healthy individuals (n=3) were stimulated with the indicated 
concentration of IFN-α in combination with IL-18 (50ng/mL). Symbols 
represent mean ± s.e.m. (a) IFN-γ (b) CD69 expression (c) Granzyme B by 
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Supplementary Figure 8. Cytokine-mediated cell activation. 
PBMC’s (n=8) from healthy individuals were directly stimulated for 24 h (black 
bars) with IFN-α, IL-12, IL-15, IL-18 or indicated combinations thereof. Bars 
and symbols represent mean ± s.e.m. IFN-γ expression by 
CD8+CD161++Vα7.2- (a), CD4+CD161++Vα7.2+ (b), CD4-CD8-CD161++Vα7.2- 
(c), or CD8+CD161- T cells (d). Statistical significance was determined with 
Kruskal-Wallis test followed by Dunns’ test. ns > 0.05,  *P  0.05, **P ≤  0.01, 
***P ≤  0.001, ****P ≤  0.0001.  
Supplementary Figure 9
 
Supplementary Figure 9 Bulk CD4 and CD8 T cells do not respond to Type I 
Interferons in vivo. PBMC’s from healthy controls or HCV patients at baseline, 
during or end of treatment with either SOF + RBV or SOF + RBV/PEG-IFN 
were analysed by flow cytometry. CD69 expression on CD4+ T cells (a) or 
CD8+ T cells (b) was measured. Bars represent means ± s.e.m. Statistical 
significance was determined with the Kruskal-Wallis test followed by Mann-
Whitney test. ns > 0.05. Abbreviations: HC, healthy controls; PEG-IFN, 









































































Supplementary Figure 10 
 
Supplementary Figure 10. Virally activated MAIT cells can limit virus 
replication. Mock or HCV-treated macrophages (MOI=1) were co-cultured with 
CD8+ T-cells from healthy individuals (n=4) for 24 h. Supernatants were 
transferred to hepatocyte lines infected with HCV expressing luciferase 
(MOI=0.1) and viral replication was measured after 96 hours. Data are from 
one experiment with three technical repeats. Bars represent means ± s.e.m. 
Statistical significance was determined with a Wilcoxon matched-paired test. 
























Supplementary Figure 11 
 
 
Supplementary Figure 11. Illustrated model of MAIT cell triggering by 
viruses. In response to viruses, antigen presenting cells, such as Dendritic 
cells, Alveolar Macrophages and Kupffer cells, are able to activate 
CD161++CD8+ T cells, by expressing cytokines, independent of MR1 antigen 
presentation. IL-18 in combination with other innate signals, such as IL-12, IL-
15 and type I IFNs, is critical in stimulating MAIT cells. MAIT-cells highly 
express the IL-18 receptor and in response to stimulation express CD69, 
produce IFN-γ and Granzyme B.   
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Supplementary Figure 12 
 
Supplementary Figure 12.	   Flow cytometry gating strategy used to define 


























Clinical characteristics of 20 DENV infected patients suffering from dengue 
fever (DF) or dengue haemorrhagic fever (DHF1-4). DHF is divided into four 
grades according to the disease severity: patients with DHF1 and 2 
having increased vascular permeability and patients with DHF3 and 4 
developing shock due to severe plasma loss. Blood samples were obtained 
from these individuals at several time points during the acute and 
convalescent phase of infection. Laboratory confirmation of DENV infection 
and the serotype (DENV1-4) were determined by RT-PCR detection of DENV 
nucleic acid. Abbreviations: DENV, dengue virus; DHF, dengue haemorrhagic 
fever; DF, dengue fever. 
 
 
Patient # Sex JE vac Age Diagnosis Type Serotype 
K01-0029 F Y 13 DHF2 secondary DENV1 
K01-0023 F Y 9 DHF1 secondary DENV1 
K01-0030 M Y 9 DHF1 secondary DENV2 
K02-0032 F N 11 DHF2 secondary DENV2 
K03-0003 M unknown 8 DHF3 secondary DENV1 
K03-0005 M Y 6 DHF2 secondary DENV1 
K02-0018 F N 9 DHF1 secondary DENV2 
K03-0013 M Y 10 DHF1 secondary DENV2 
K03-0092 M N 11 DHF2 secondary DENV1 
K03-0099 M Y 12 DHF1 secondary DENV2 
K03-0038 M Y 5 DHF2 secondary DENV1 
K02-0105 F Y 4 DF secondary DENV2 
K01-0028 M unknown 6 DF secondary DENV1 
K02-0102 F Y 9 DF secondary DENV1 
K02-0105 F Y 4 DF secondary DENV2 
K02-0016 M Y 9 DF secondary DENV1 
K03-0073 F Y 2 DF secondary DENV1 
K02-0037 F Y 12 DF secondary DENV1 
K03-0063 M Y 5 DF secondary DENV2 
K02-0031 M N 12 DF secondary DENV2 
K03-0093 M Y 3 DF secondary DENV4 
K01-0013 M unknown 5 DF primary DENV1 
Supplementary Table 2. Summary of influenza virus-infected patients. 
Patient ID Sex Age Care Co-morbidities 
1 M 48 ICU 
 2 F 59 ICU CLL (since 1992) 
3 F 59 ICU COPD 
4 M 54 ICU COPD 
5 F 29 ICU 5 days post partum 
6 F 45 ward Pregnancy (third trimester) 
7 F 34 ward Pregnancy (third trimester) 
8 M 60 ward Diabetes mellitus,  
    
epilepsy 
9 F 68 ward CLL 
     
Influenza-infected patients were admitted either to the general ward or ICU. 
Patients were recruited from two hospitals based in Oxford and Glasgow 
during the 2009 H1N1 pandemic. Patients had concomitant conditions as 
documented in Table 2, but were not on immunosuppressant at the point of 
sampling. Two patients were pregnant, and one was six days post-partum. 
Abbreviations: CLL, Chronic lymphocytic leukemia; COPD, Chronic 
obstructive pulmonary disease 
 
 




  patient ID gender age 
 
patient ID gender age 
855 F 44 
 
120 F 64 
672 F 36 
 
144 F 62 
940 M 32 
 
146 M 61 
615 M 41 
 
148 F 63 
765 M 52 
 
152 M 60 
854 M 36 
 
185 F 67 
318 F 49 
 
226 M 47 
581 F 60 
 
279 M 59 
197 F 53 
 
307 F 53 
191 M 64 
 
376 M 59 
256 M 55 
 
205/821 M 53 
603 M 52 
 
sustained virological response 
144 F 47 
 
patient ID gender age 
146 M 56 
 
730 M 59 
148 F 68 
 
134 F 53 
205/821 M 64 
 
292 M 59 
126 M 58 
 
472 M 53 
non-response 
  
325 M 59 
patient ID gender age 
 
618 M 53 
191 M 64 
 
238 M 59 
262 M 62 
 
157 M 53 
306 M 61 
 
400 M 59 
327 M 63 
 
449 M 53 
349 M 60 
 
unkown unkown 
 383 F 67 
 
385 M 53 
391 M 47 
 
spontaneous clearance 
403 F 59 
 
patient ID gender age 
594 M 53 
 
806 M 41 
500 unknown unknown 
 
861 M 55 
602 M 51 
 
884 M 39 
603 M 52 
 
900 M 48 
629 F 51 
 
113 M 67 
634 M 60 
 
975 M 53 
639 F 59 
 
720 F 64 
722 f 63 
 
871 F 62 
    
906 F 61 
    
1014 M 63 
    
1041 M 60 
    
1052 M 67 
   
Samples were collected from the Hepatitis Clinic at the John Radcliffe 
Hospital, Oxford, UK. 
 
 






















PBMC from the BOSON clinical trial were used. BOSON is a randomized, 
open-label, phase 3 study testing Sofosbuvir plus Ribavirin with or without 
pegylated interferon-alpha in patients with HCV Genotype 3 and Treatment-
experienced cirrhotic patients with HCV Genotype 2. PBMCs were processed 











1 SOF + RBV US 2 
2 SOF + RBV US 3a 
3 SOF + RBV US 3a 
4 SOF + RBV US 2a/2c 
5 SOF + RBV US 3a 
6 SOF + RBV US 3a 
7 SOF + RBV US 3a 
8 SOF + RBV US 3a 
9 SOF + RBV Europe 3a 
10 SOF + RBV Europe 3a 
11 SOF + RBV Europe 3a 
12 SOF + RBV Europe 3c 
13 SOF + RBV Europe 3a 
14 SOF + RBV Europe 3 
15 SOF + RBV Europe 3 
16 SOF + PEG/RBV US 3a 
17 SOF + PEG/RBV US 3a 
18 SOF + PEG/RBV US 3 
19 SOF + PEG/RBV US 3a 
20 SOF + PEG/RBV US 3a 
21 SOF + PEG/RBV US 3a 
22 SOF + PEG/RBV US 3a 
23 SOF + PEG/RBV US 2 
24 SOF + PEG/RBV US 3a 
25 SOF + PEG/RBV US 3b 
